Aptar Pharma acquires Pulmotree to expand next-generation pulmonary drug delivery technology

Aptar Pharma has acquired German inhalation technology specialist Pulmotree, adding its Kolibri platform to expand next-generation pulmonary drug delivery capabilities.

The acquisition follows an existing collaboration and brings Pulmotree's Kolibri Non-Propellant Liquid Inhaler technology into Aptar Pharma's respiratory portfolio, supporting targeted delivery of inhaled medicines.

Aptar intends to accelerate development, industrialisation and commercialisation of the platform, including potential applications for complex therapeutic molecules such as biologics, although the acquisition's financial terms were not disclosed.

Field	Content
Article Type	Deals
Acquirer	Aptar Pharma
Acquired Company	Pulmotree
Deal Type	Strategic acquisition
Transaction Status	Announced as acquired
Announcement Date	26 October 2026
Target Company Location	Germany
Acquired Technology	Kolibri Non-Propellant Liquid Inhaler platform
Technology Category	Pulmonary drug delivery
Delivery Approach	Non-propellant liquid inhalation
Therapeutic Applications	Respiratory medicines and potential complex-molecule therapies
Potential Molecule Types	Biologics and other complex therapeutic molecules
Prior Relationship	Existing Aptar Pharma-Pulmotree collaboration
Strategic Focus	Development, industrialisation and commercialisation of next-generation inhalation technology
Acquisition Consideration	Not disclosed
Financial Terms	Not disclosed
Regulatory Approval Status	No new medicine or device regulatory approval established by the acquisition announcement
What Happened	Aptar Pharma acquired Pulmotree and its Kolibri inhalation technology following an established collaboration.
Why It Matters	The acquisition broadens Aptar's respiratory drug delivery capabilities and could support development of inhaled treatments involving complex molecules.
Strategic Rationale	Integrate specialised pulmonary delivery technology to accelerate platform development and commercialisation.
Portfolio Impact	Adds the Kolibri Non-Propellant Liquid Inhaler platform to Aptar Pharma's technology portfolio.
Key Takeaway	Aptar has expanded its pulmonary drug delivery portfolio through the acquisition of Pulmotree; the purchase price was not disclosed.
What to Watch	Kolibri development milestones, industrial scale-up, pharmaceutical partnerships, regulatory progress and commercial adoption.
Primary Source	Aptar Pharma
Primary Source URL	https://www.aptar.com/news-events/aptar-pharma-acquires-pulmotree-expanding-growth-opportunities-in-next-generation-pulmonary-drug
Relevant Date	26 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com